Abstract:Abstract BackgroundNAFLD is a common metabolic disorders disease which influenced 20~30% people. NAFLD can progress to cirrhosis, liver fibrosis and even liver cancer. Liver puncture is the gold standard. However, due to its trauma and possible complications, its clinical use is currently limited. Therefore, it is of great clinical significance and value to find a noninvasive biochemical index that can diagnose NAFLD early.ObjectiveOur aim was to identify the potential biomarkers in NAFLD people in early stage via untargeted metabolomics study.MethodsIn our research, From January to October 2019, 224 patients aged 18-55 were selected from the outpatient department and ward of gastroenterology department of Putuo Hospital in Shanghai.According to the NAFLD diagnostic criteria of the guidelines for diagnosis and treatment of nonalcoholic fatty liver disease (2018) formulated by the National workship on Fatty liver and alcoholic liver disease and Chinese Society on Hepatology, they were divided into the healthy control group and the experimental group.Besides,on the same day, the height, weight, waist, BMI, blood pressure and heart rate of patients were measured, and fasting blood was taken to obtain blood glucose,ALT, AST, TB, DB, TP, ALB, Che, ALP, γ - GT, TG, TC, HDL-C, LDL-C and other serum data.Serum samples were analyzed using LC/MS and data was processed by SIEVE software and simca-P to validate the potential biomarkers. The altered metabolites were identified by variable importance in projection value (VIP > 1) and ANOVA ( p< 0.01). The pathway analysis was performed by using MetaboAnalyst 4.0. In addition, our project has passed the review of ethics committee of Putuo Hospital Affiliated to Shanghai University of traditional Chinese medicine, and its ethics approval number is ptec-a-2018-49-1.ResultsThe serum biochemical indicators of early NAFLD patients showed no significant difference with NC ( p>0.05 ). While there was significant difference of blood lipids indicators between NAFLD and NC ( p<0.001 ). Finally, 55 metabolites were identified and the AUC of ROC curve results showed that new identified biomarkers owned high predictability and reliability. ConclusionIt is found that 15 metabolites in serum were of great diagnostic value in early NAFLD patients. AUC of these biomarkers (>0.9) were much higher than clinical indicators (0.770). This may be worth further research in the clinic.

Serum CK 18-M30 Reflect Liver Pathological Severity During NAFLD Progression in a Rat Model

Expressions of Key Regulatory Genes of the Lipid Metabolism in Livers During the Development of Rat Non-alcoholic Fatty Liver Disease

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Serum CK-18 M30 levels in patients with nonalcoholic fatty liver disease

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.

The Significance of IL-28B and CK-18 M30 Levels in the Diagnosis of Non-Alcoholic Steatohepatitis in SD Rats.

Serum Metabolome Alterations in Patients with Early Nonalcoholic Fatty Liver Disease.

Large-scale Analysis of Factors Influencing Nonalcoholic Fatty Liver Disease and Its Relationship with Liver Enzymes.

A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Clinical value of Serum CK-18 M30 levels in patients with nonalcoholic steatohepatitis

Study on Relationship Between Fat-Rich Diet-Induced Nonalcoholic Fatty Liver Disease and Endoplasmic Reticulum Stress in Rats

Serum Amino Acids Profiling In NAFLD Mice

Progress in Serum Markers for Non-Alcoholic Fatty Liver Disease

Distinct Changes in Serum Metabolites and Lipid Species in the Onset and Progression of NAFLD in Obese Chinese

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

Correlation of Serum Adiponectin Level and Adiponectin Receptor Expression with Hepatic Pathological Changes in Rats with Non-Alcoholic Fatty Liver Diseases

Serum metabolomic profiling reveals an increase in homocitrulline in Chinese patients with nonalcoholic fatty liver disease: a retrospective study

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

[Advances in epidemiology and serum markers for the noninvasive diagnosis of nonalcoholic fatty liver disease].